Literature DB >> 10381115

Comparative in-vitro activity of voriconazole (UK-109,496) and six other antifungal agents against clinical isolates of Scedosporium prolificans and Scedosporium apiospermum.

M Cuenca-Estrella1, B Ruiz-Díez, J V Martínez-Suárez, A Monzón, J L Rodríguez-Tudela.   

Abstract

We report the in-vitro susceptibility of 27 clinical isolates of Scedosporium apiospermum and 43 of Scedosporium prolificans. S. apiospermum was resistant to fluconazole and flucytosine, with variable susceptibility to amphotericin B, itraconazole, ketoconazole and susceptible to miconazole. Voriconazole was much more active than fluconazole and flucytosine, more active than amphotericin B, itraconazole and ketoconazole and was as active as miconazole against S. apiospermum isolates. Voriconazole and the other six antifungal agents showed low activity against S. prolificans isolates.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10381115     DOI: 10.1093/jac/43.1.149

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  59 in total

1.  Successful control of disseminated Scedosporium prolificans infection with a combination of voriconazole and terbinafine.

Authors:  B P Howden; M A Slavin; A P Schwarer; A M Mijch
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-02-14       Impact factor: 3.267

2.  Interlaboratory evaluation of hematocytometer method of inoculum preparation for testing antifungal susceptibilities of filamentous fungi.

Authors:  J L Rodriguez-Tudela; Erja Chryssanthou; Evangelia Petrikkou; Juan Mosquera; David W Denning; Manuel Cuenca-Estrella
Journal:  J Clin Microbiol       Date:  2003-11       Impact factor: 5.948

3.  The pharmacokinetics of voriconazole.

Authors:  Atholl Johnston
Journal:  Br J Clin Pharmacol       Date:  2003-12       Impact factor: 4.335

Review 4.  [Strategies for antifungal treatment failure in intensive care units].

Authors:  C Arens; M Bernhard; C Koch; A Heininger; D Störzinger; T Hoppe-Tichy; M Hecker; B Grabein; M A Weigand; C Lichtenstern
Journal:  Anaesthesist       Date:  2015-09       Impact factor: 1.041

5.  In vitro interaction of terbinafine with itraconazole against clinical isolates of Scedosporium prolificans.

Authors:  J Meletiadis; J W Mouton; J L Rodriguez-Tudela; J F Meis; P E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

6.  Molecular mycological diagnosis and correct antimycotic treatments.

Authors:  Nicasio Mancini; Cristina M Ossi; Mario Perotti; Massimo Clementi; Daniel B DiGiulio; Joanna M Schaenman; Jose G Montoya; Nancy B McClenny; Gerald J Berry; Laurence F Mirels; Michael G Rinaldi; Annette W Fothergill
Journal:  J Clin Microbiol       Date:  2005-07       Impact factor: 5.948

7.  Antifungal susceptibilities of the species of the Pseudallescheria boydii complex.

Authors:  Fèlix Gilgado; Carolina Serena; Josep Cano; Josepa Gené; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2006-10-02       Impact factor: 5.191

8.  In vitro synergistic interaction between amphotericin B and pentamidine against Scedosporium prolificans.

Authors:  Javier Afeltra; Eric Dannaoui; Jacques F G M Meis; Juan L Rodriguez-Tudela; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

9.  Correlation between in vitro susceptibility of Scedosporium apiospermum to voriconazole and in vivo outcome of scedosporiosis in guinea pigs.

Authors:  Javier Capilla; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

Review 10.  Infections caused by Scedosporium spp.

Authors:  Karoll J Cortez; Emmanuel Roilides; Flavio Quiroz-Telles; Joseph Meletiadis; Charalampos Antachopoulos; Tena Knudsen; Wendy Buchanan; Jeffrey Milanovich; Deanna A Sutton; Annette Fothergill; Michael G Rinaldi; Yvonne R Shea; Theoklis Zaoutis; Shyam Kottilil; Thomas J Walsh
Journal:  Clin Microbiol Rev       Date:  2008-01       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.